Marked Strain-Specific Differences in the SU5416 Rat Model of Severe Pulmonary Arterial Hypertension

被引:71
|
作者
Jiang, Baohua [1 ]
Deng, Yupu [1 ]
Suen, Colin [1 ,2 ]
Taha, Mohamad [1 ,2 ]
Chaudhary, Ketul R. [1 ]
Courtman, David W. [1 ]
Stewart, Duncan J. [1 ,2 ]
机构
[1] Ottawa Hosp Res Inst, Sinclair Ctr Regenerat Med, Ottawa, ON, Canada
[2] Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON, Canada
基金
加拿大健康研究院;
关键词
pulmonary arterial hypertension; right ventricular remodeling; vascular remodeling; rodent strains; SU5416; BLOOD-INSTITUTE; PATHOLOGY; CELLS; PROLIFERATION; MECHANISMS; APOPTOSIS; SURVIVAL; CONFERS;
D O I
10.1165/rcmb.2014-0488OC
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We assessed the pulmonary hemodynamic response to vascular endothelial growth factor receptor, type 2, inhibition using SU5416 (SU) with and without chronic hypoxia (CH) in different background strains and colonies of rats. A single subcutaneous injection of SU (20 mg/kg) or vehicle was administered to different substrains of Sprague-Dawley (SD) rats, and they were compared with Lewis and Fischer rats, with and without exposure to CH (10% O-2 for 3 wk). Remarkably, a unique colony of SD rats from Charles River Laboratories, termed the SD-hyperresponsive type, exhibited severe pulmonary arterial hypertension (PAH) with SU alone, characterized by increased right ventricular systolic pressure, right ventricular/left ventricular plus septal weight ratio, and arteriolar occlusive lesions at 7-8 weeks (all P < 0.0001 versus vehicle). In contrast, the other SD substrain from Harlan Laboratories, termed SD-typical type, as well as Fischer rats, developed severe PAH only when exposed to SU and CH, whereas Lewis rats showed only a minimal response. All SD-typical type rats survived for up to 13 weeks after SU/CH, whereas SD-hyperresponsive type rats exhibited mortality after SU and SU/CH (35% and 50%, respectively) at 8 weeks. Fischer rats exposed to SU/CH exhibited the greatest mortality at 8 weeks (78%), beginning as early as 4 weeks after SU and preceded by right ventricle enlargement. Of note, a partial recovery of PAH after 8 weeks was observed in the SD-typical type substrain only. In conclusion, variation in strain, even between colonies of the same strain, has a remarkable influence on the nature and severity of the response to SU, consistent with an important role for genetic modifiers of the PAH phenotype.
引用
收藏
页码:461 / 468
页数:8
相关论文
共 50 条
  • [41] Protracted Endothelial Cell Apoptosis Leads To Direct Microvascular Loss As A Major Mechanism Of Severe Pulmonary Arterial Hypertension In The Rat Su5416-Hypoxia Model
    Deng, Y.
    Chaudhary, K. R.
    Yang, A.
    Rowe, K. J.
    Stewart, D. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [42] The Isoquinoline-Sulfonamide Compound H-1337 Attenuates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension in Rats
    Shoji, Hiroki
    Yoshida, Yoko
    Sanada, Takayuki Jujo
    Naito, Akira
    Maruyama, Junko
    Zhang, Erquan
    Sumi, Kengo
    Sakao, Seiichiro
    Maruyama, Kazuo
    Hidaka, Hiroyoshi
    Tatsumi, Koichiro
    CELLS, 2022, 11 (01)
  • [43] Potential Contribution Of Precursor Cells To Angioproliferation In The SU5416/chronic Hypoxia Model Of Severe PAH
    Farkas, L.
    Farkas, D.
    Kraskauskas, D.
    Natarajan, R.
    Bogaard, H.
    Voelkel, N. F.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [44] Overexpressed pigment epithelium-derived factor alleviates pulmonary hypertension in two rat models induced by monocrotaline and SU5416/ hypoxia
    Miao, Haoran
    Hui, Hongliang
    Fan, Wenbin
    Lin, Yangui
    Li, Huaming
    Li, Dan
    Luo, Min
    Qiu, Fan
    Jiang, Bo
    Zhang, Yiqian
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 172
  • [45] The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats
    Lang, Michaela
    Kojonazarov, Baktybek
    Tian, Xia
    Kalymbetov, Anuar
    Weissmann, Norbert
    Grimminger, Friedrich
    Kretschmer, Axel
    Stasch, Johannes-Peter
    Seeger, Werner
    Ghofrani, Hossein Ardeschir
    Schermuly, Ralph Theo
    PLOS ONE, 2012, 7 (08):
  • [46] STING mediates SU5416/hypoxia-induced pulmonary arterial hypertension in rats by regulating macrophage NLRP3 inflammasome activation
    Wu, Dan-dan
    Deng, Yan
    Liao, Juan
    Xie, Shan-shan
    Meng, Hui
    Lan, Fang
    IMMUNOBIOLOGY, 2023, 228 (02)
  • [47] Mineralocorticoid receptor antagonist treatment of established pulmonary arterial hypertension improves interventricular dependence in the SU5416-hypoxia rat model
    Lu, Mengyun
    Chen, Li-Yuan
    Gairhe, Salina
    Mazer, Adrien J.
    Anderson, Stasia A.
    Nelson, Jasmine N. H.
    Noguchi, Audrey
    Siddique, Mohammad Abdul Hai
    Dougherty, Edward J.
    Zou, Yvette
    Johnston, Kathryn A.
    Yu, Zu-Xi
    Wang, Honghui
    Wang, Shuibang
    Sun, Junfeng
    Solomon, Steven B.
    Vanderpool, Rebecca R.
    Solomon, Michael A.
    Danner, Robert L.
    Elinoff, Jason M.
    AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2022, 322 (03) : L315 - L332
  • [48] The need for hypoxic exposure in experimental PAH - Comment on Chen et al.: a novel rat model of pulmonary hypertension induced by mono treatment with SU5416
    Michiel Alexander de Raaf
    Ingrid Schalij
    Harm Jan Bogaard
    Hypertension Research, 2020, 43 : 1313 - 1314
  • [49] A bradykinin antagonist and a caspase inhibitor block severe pulmonary hypertension in rats evoked by hypoxia and VEGF-R2 inhibitor SU5416
    Stewart, JM
    Taraseviciene-Stewart, L
    Hirth, P
    Voelkel, NF
    Tuder, RM
    Gera, L
    FASEB JOURNAL, 2001, 15 (05): : A858 - A858
  • [50] Combination of CARSKNKDC(CAR) peptide with sildenafil in the treatment of pulmonary hypertension associated with emphysema induced by SU5416 in rats
    Goto, Norihiko
    Wada, Yosuke
    Kitaguchi, Yoshiaki
    Yasuo, Masanori
    Hanaoka, Masayuki
    RESPIROLOGY, 2023, 28 : 79 - 79